Medipron Accelerates New Drug Development by Integrating and Relocating Headquarters and Central Research Institute

[Asia Economy Reporter Hyunseok Yoo] Mediphron Divity announced on the 23rd that it will consolidate and relocate its headquarters and central research institute to Gasan Digital Complex.

Mediphron will relocate to Gasan Digital Complex on the 26th, comprehensively considering the securing of excellent talent essential for conducting Phase 1 clinical trials of non-narcotic analgesics, establishment of state-of-the-art research facilities, and accessibility to clinical trial institutions.

The central research institute currently located in Ansan faced difficulties due to aging research equipment and challenges in securing top talent, but this relocation will resolve these issues.

Since being acquired by Brain Contents Group, Mediphron has expanded its bio-business based on its financial strength. Accordingly, in May, it invested in NewMice, the world’s first bio-venture developing an anti-atherosclerosis treatment drug, founded by Dr. Changsoo Kim, a former FDA researcher and professor of biomedical engineering at the University of Wisconsin. Furthermore, by undertaking the large-scale investment of relocating the central research institute, it has secured a foundation for success in the bio-business sector.

Yoo Youngdong, head of Mediphron’s research institute, stated, “The consolidation and relocation of the headquarters and central research institute reflect the major shareholder’s determination to enhance work efficiency and create synergy, accelerating and ensuring the success of the Phase 1 clinical trial of the non-narcotic analgesic and the commercialization of the ‘Alzheimer’s Disease Early Diagnosis Support Medical Device.’ This will be a new starting point for Mediphron.”

Mediphron is a bio new drug development specialized company that independently discovers new drug candidates, builds evaluation models, and possesses the technology and infrastructure to conduct animal experiments. Recently, it received Phase 1 clinical trial approval for a non-narcotic analgesic from the Ministry of Food and Drug Safety, and is awaiting product approval for the ‘Alzheimer’s Disease Early Diagnosis Support Medical Device,’ completed last year through joint research and development with Quantamatrix.

This content was produced with the assistance of AI translation services.